Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 16

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 16
---
 income (expense):   Interest income19,689 11,444 4,542 Interest expense(16,569)(20,306)(39,976)Gain (loss) on early extinguishment of debt7,518 (16,926)— Other, net(373)(186)(11,288)Total other income (expense), net10,265 (25,974)(46,722)(Loss) income before income taxes(63,106)61,701 13,302 Income tax (expense) benefit(36,454)(19,746)2,607 Net (loss) income$(99,560)$41,955 $15,909 Net (loss) income per share:   Basic net (loss) income per common share$(2.15)$0.91 $0.35 Diluted net (loss) income per common share$(2.15)$0.89 $0.34 Weighted average common shares outstanding:   Basic46,245 46,222 45,521 Diluted46,245 51,979 46,538 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-6

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In thousands) Year Ended December 31, 202420232022Net (loss) income$(99,560)$41,955 $15,909 Other comprehensive income (loss):   Net unrealized gain (loss) on investments, net of tax66 647 (662)Foreign currency translation adjustments30 (20)115 Total other comprehensive income (loss)96 627 (547)Comprehensive (loss) income$(99,464)$42,582 $15,362 

See accompanying notes to consolidated financial statements

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-7

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022

(In thousands) Number of shares outstandingAdditionalPaid-InCapitalAccumulated